Circulating epigenomic biomarkers correspond with kidney disease susceptibility in high-risk populations with type 2 diabetes mellitus
Authors' conclusion
Novel epigenomic scores can improve diagnostic performance over clinical modelling using albuminuria and GFR alone and can distinguish DKD susceptibility.
Study context
- Population
- High-risk populations with T2D: Aboriginal Australians (PROPHECY) and Thai people (THEPTARIN diabetes registry)
- Participants
- 89 vs 128
- Comparison
- People with vs without diabetic kidney disease (DKD)
- PROPHECYn = 89
- THEPTARINn = 128
- Outcome
- Differential gene methylation and expression with DKD risk
Methodological detailsdiscovery cohort, external independent validation cohort, KDIGO guidelines used to classify DKD; mRNA levels linked to albuminuria and eGFR
- Discovery cohort
- External independent validation cohort
- KDIGO guidelines used to classify DKD; mRNA levels linked to albuminuria and eGFR
Performance
As reported in the abstract
- Increased DKD risk was associated with reduced methylation and elevated gene expression in PROPHECY; externally validated in THEPTARIN
Original publication
Circulating epigenomic biomarkers correspond with kidney disease susceptibility in high-risk populations with type 2 diabetes mellitus. Diabetes Res Clin Pract. Published 24 September 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →